Clinical Trial News and Research

RSS

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.

16 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

$New device holds promise for improving the delivery of stem cell therapy for non-healing fractures$

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a "proof-of-concept" clinical trial to test the safety and efficacy of the device in the coming months.

16 Jan 2015

YODA Project announces availability of clinical trial data for medical devices

The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made possible through collaboration with Johnson & Johnson.

15 Jan 2015

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015.

15 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

High vitamin D levels boost survival for metastatic colorectal cancer patients

According to a new study led by researchers at Dana-Farber Cancer Institute, clinical trial patients with metastatic colorectal cancer who had high levels of vitamin D in their bloodstream prior to treatment with chemotherapy and targeted drugs, survived longer, on average, than patients with lower levels of the vitamin.

14 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

New way to measure upper extremity movement in muscular dystrophy patients

Researchers at Nationwide Children's Hospital have developed a way to measure upper extremity movement in patients with muscular dystrophy using interactive video game technology. Their hope is to expand inclusion criteria for clinical trials to incorporate patients using wheelchairs.

12 Jan 2015

Study demonstrates that pelvic floor muscle training improves erectile function

Preliminary results of a four-month clinical trial offer hope for the thousands of baby boomer men turning 50 every minute, with nearly 6-in-10 of them experiencing erectile dysfunction. Proving pelvic floor exercise can help turn back the clock on sexual decline, the study demonstrates that weighted resistance training improves erectile function in both healthy men and those with erectile dysfunction.

12 Jan 2015

Sheffield breast cancer patient takes part in new drug research trial

A SHEFFIELD patient has become the first in the world to take part in a new drug research trial aiming to better control secondary breast cancer, or cancer which has spread to other parts of the body including the bones, liver and lungs for longer.

12 Jan 2015

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer.

12 Jan 2015

EMA accepts Praluent (alirocumab) MAA for review

Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.

12 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

8 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc.

8 Jan 2015

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

8 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Clinical Trial News and Research

Unmet medication need in neuropathic pain

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

YODA Project announces availability of clinical trial data for medical devices

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

CAR T-cell therapy enters into Phase I clinical trial

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

High vitamin D levels boost survival for metastatic colorectal cancer patients

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

New way to measure upper extremity movement in muscular dystrophy patients

Study demonstrates that pelvic floor muscle training improves erectile function

Sheffield breast cancer patient takes part in new drug research trial

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

EMA accepts Praluent (alirocumab) MAA for review

Two new ODYSSEY trials meet primary efficacy endpoints

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery